Lilly Retatrutide Cuts Weight

What happened

Lilly said its experimental obesity drug retatrutide produced the strongest late-stage weight-loss results yet for the class. At the highest dose, people with type 2 diabetes lost about 18.8% of body weight, while people with obesity without diabetes lost about 25%. Retatrutide is a triple agonist, meaning it targets GLP-1, GIP and glucagon to curb appetite, improve blood sugar and raise energy use. Researchers and Lilly said its safety profile was generally similar to other GLP-1-type drugs. In the diabetes trial, 2,047 adults in eight countries received weekly shots for 80 weeks with diet and exercise counseling. Retatrutide is not approved by any regulator, but demand is expected to intensify.

How each side covered it

From the left

Left-leaning outlets framed retatrutide as a next-generation breakthrough, while tempering the promise with its experimental status. The Guardian leaned into the scale of the potential benefit, saying it could help people shift “enormous amounts” of excess weight. The Guardian also stressed benefits beyond weight loss, including blood sugar and inflammation. It highlighted the triple-hormone design as the feature separating retatrutide from drugs like Wegovy and Mounjaro.